Dietrich Seidel

This inventor holds 12 USPTO granted patents and 4 published patent applications and 6 EPO patents. Top assignees: B. Braun Melsungen Ag, Sebo Gmbh, B. Braun Medizintechnologie Gmbh. Active years: 1996-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dietrich Seidel. Retrieved from https://idiyas.com/inventor/dietrich-seidel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 4)

% Patents Active = 66.7

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 1.9

ph-index = 5

Forward Citations = 146(Granted Patents)

Company Filing History:

4 out of 386

B. Braun Melsungen Ag

B. Braun Medizintechnologie Gmbh

patents

4. 1 out of 1,164

Boehringer Mannheim Gmbh

patents

5. 1 out of 29

Novartis International Pharmaceutical, Ltd.

7. 1 out of 834,659

Other

patents

Years Active: 1996-2022

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11278566 - Agent for use for inflammatory conditions of mucous membranes (2022-03-22),

2. 9012137 - Disintegration of cellular components in whole blood by freeze-thawing (2015-04-21),

3. 8231838 - Method and device for processing a biological fluid for analyte determination (2012-07-31),

4. 7799579 - Method and device for processing a biological fluid for analyte determination (2010-09-21),

5. 7608189 - Device for removing bacterial lipopolysaccharides and/or lipoteichoic acids from protein-containing fluids and its use for the treatment of sepsis (2009-10-27),

6. 7553482 - Use of a phosphate adsorbent to combat vascular diseases (2009-06-30),

7. 6103126 - Process for the selective elimination of inorganic phosphate from (2000-08-15),

8. 5846426 - Process for the selective elimination of inorganic phosphate from (1998-12-08),

9. 5795786 - Process and reagent for the specific determination of LDL in serum (1998-08-18),

10. 5679775 - Process and device for the simultaneous extracorporeal elimination of (1997-10-21),

11. 5679260 - Process for simultaneously removing tumour necrosis factor .alpha. and (1997-10-21),

12. 5514281 - Process for the selective elimination of inorganic phosphate from (1996-05-07),

Title: Dietrich Seidel: Innovator in Pharmaceutical Applications

Introduction

Dietrich Seidel is a notable inventor based in Feldafing, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of inflammatory conditions. With a total of 12 patents to his name, Seidel's work has had a considerable impact on medical science.

Latest Patents

One of Seidel's latest patents is an agent designed for use in inflammatory conditions of mucous membranes. This invention involves an agent comprising anion-exchange groups that can adsorb bacterial lipopolysaccharides (LPS) and/or lipoteichoic acids (LTA). It is intended for the prevention and treatment of inflammatory conditions and diseases affecting the oral cavity or vaginal region. Additionally, he has developed a method for disintegration of cellular components in whole blood through freeze-thawing. This method is particularly useful for preparing biological samples for analyte detection.

Career Highlights

Throughout his career, Dietrich Seidel has worked with prominent companies such as B. Braun Melsungen AG and Sebo GmbH. His innovative approaches and dedication to research have led to advancements in pharmaceutical applications.

Collaborations

Seidel has collaborated with notable professionals in his field, including Karl-Siegfried Boos and Klaus Spengler. Their combined expertise has contributed to the success of his inventions.

Conclusion

Dietrich Seidel's contributions to the pharmaceutical industry through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to influence the treatment of inflammatory conditions, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.